Vor Biopharma Inc. VOR · Stock Open Vor Biopharma Inc. in new tab
Vor Biopharma Inc. Analysis (VOR)
Is Vor Biopharma Inc. a good investment? Vor Biopharma Inc. (VOR) is currently trading at 21.89 USD. Market analysts have a consensus price target of 39.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.13. This relatively low multiple may signal that Vor Biopharma Inc. is undervalued compared to historical market norms.
Earnings Schedule: Vor Biopharma Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -3.81.
Investor FAQ
Does Vor Biopharma Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Vor Biopharma Inc.?
Vor Biopharma Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of 174.71.
Company Profile
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 19, 2025 | 1:20 |
Community Discussion